Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 680-687

  Zhang, Xiaoping ^a   Fettner, Scott ^a   Zwanziger, Elke ^b   Rowell, Lucy ^c   Salgo, Miklos ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIFABUTIN; RITONAVIR; SAQUINAVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RIFABUTIN; RITONAVIR; SAQUINAVIR; YOUNG ADULT;

EID: 78751679140     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00992-10     Document Type: Article

References (18)

1. PRKaletra® lopinavir/ritonavir oral solution (80/20 mg/mL) human immunodeficiency virus (HIV) protease inhibitor. Abbott Laboratories, Ltd., St-Laurent, Quebec, Canada. http://www.abbott.ca/ static/content/document/Kaletra-PM-09AUG10.pdf.
2. Abbott Laboratories. 2010. Norvir® (ritonavir capsules) soft gelatin (ritonavir oral solution) prescribing information. Abbott Laboratories, North Chicago, IL. http://rxabbott.com/pdf/norpi2a.pdf.
3. Apseloff, G. 2003. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin. Pharmacol. Ther. 74:591-592.
4. Banker, M. J., T. H. Clark, and J. A. William. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. 92:967-974.
5. Boulanger, C., et al. 2009. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin. Infect. Dis. 49:1305-1311.
6. Burman, W. J., K. Gallicano, and C. Peloquin. 1999. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin. Infect. Dis. 28:419-430.
7. Cahn, P., H. Perez, G. Ben, and C. Ochoa. 2003. Tuberculosis and HIV: a partnership against the most vulnerable. J. Int. Assoc. Physicians AIDS Care 2:106-123.
8. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health. 9 August 2006. Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3. pdf. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.
9. Cato, A., et al. 1998. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin. Pharmacol. Ther. 63:414-421.
10. Di Perri, G., et al. 2005. Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy. Expert Opin. Drug Saf. 4:821-836.
11. Genentech USA, Inc. 2010. Invirase® (saquinavir mesylate) capsules and tablets prescribing information. Genentech USA, Inc. South San Francisco, CA. http://www.gene.com/gene/products/information/invirase/pdf/pi.pdf.
12. LeBel, M., et al. 1998. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J. Clin. Pharmacol. 38:1042-1050.
13. Moyle, G. J., et al. 2002. Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV. Br. J. Clin. Pharmacol. 54:178-182.
14. Pfizer Inc. 2007. Mycobutin® (rifabutin) capsules, USP prescribing information. Pfizer Inc., New York, NY. http://www.pfizer.com/files/products/ uspi-mycobutin.pdf.
15. Schmitt, C., M. Riek, E. Winters, M. Schultz, and S. Grange. 2009. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch. Drug Info. 2:8-16.
16. Veldkamp, A. I., R. M. W. Hoetelmans, J. H. Beijnen, J. W. Mulder, and P. L. Meenhorst. 1999. Ritonavir enables combined therapy with rifampin and saquinavir. Clin. Infect. Dis. 29:1586.
17. Weiner, M., et al. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491.
18. World Health Organization. 2008. Global tuberculosis control 2008: surveillance, planning, financing. WHO Report 2008. WHO publication WHO/HTM/TB/2008.393. World Health Organization, Geneva, Switzerland http://www.who.int/tb/publications/global-report/2008/pdf/fullreport.pdf.